Patents by Inventor Coralie BELANGER

Coralie BELANGER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220119543
    Abstract: The present invention relates to humanized antibodies that specifically hind to human transferrin receptor and their use in treating cancer and inflammatory disorders.
    Type: Application
    Filed: December 9, 2021
    Publication date: April 21, 2022
    Inventors: Pierre LAUNAY, Coralie BELANGER, Hervé SOUCHET
  • Patent number: 11230605
    Abstract: The present invention relates to humanized antibodies that specifically bind to human transferrin receptor and their use in treating cancer and inflammatory disorders.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: January 25, 2022
    Assignee: INATHERYS
    Inventors: Pierre Launay, Coralie Belanger, Hervé Souchet
  • Publication number: 20210138083
    Abstract: The present invention relates to antibody-drug conjugates, wherein the antibody specifically binds to TfR, the transferrin receptor, and wherein the drug is preferably chosen among a cytotoxic drug. Such antibody-drug conjugates are useful in particular in treating proliferative diseases including cancers, such as lymphoma or leukaemia.
    Type: Application
    Filed: April 9, 2019
    Publication date: May 13, 2021
    Inventors: Pierre LAUNAY, Hervé SOUCHET, Coralie BELANGER
  • Publication number: 20190352415
    Abstract: The CD71 receptor is used as a target in the prognosis and/or treatment of endometriosis, and to a test for the prognosis or therapeutic monitoring of endometriosis, targeting this receptor.
    Type: Application
    Filed: January 19, 2018
    Publication date: November 21, 2019
    Applicants: ENDODIAG, INATHERYS
    Inventors: Pierre LAUNAY, Coralie BELANGER, Cécile REAL
  • Publication number: 20190092870
    Abstract: The present invention relates to humanized antibodies that specifically bind to human transferrin receptor and their use in treating cancer and inflammatory disorders.
    Type: Application
    Filed: July 21, 2016
    Publication date: March 28, 2019
    Inventors: Pierre LAUNAY, Coralie BELANGER, Hervé SOUCHET